Clinical Trials - November 9, 2021
Lundbeck reports positive results for Vyepti
Lundbeck has announced positive results from the DELIVER study assessing the efficacy and safety of Vyepti (eptinezumab) 100mg and 300mg IV infusion in patients with chronic or episodic migraine who had experienced two to four previous preventive treatment failures due to lack of efficacy or intolerable side effects. The study met its primary objective of […]
Acquisition - October 22, 2021
Lundbeck acquires exclusive rights to APB-A1 from AprilBio
Lundbeck has entered into a definitive agreement with AprilBio, a biopharmaceutical company based in South Korea. Under the agreement between the two companies, Lundbeck receives exclusive, worldwide rights to research, develop and commercialize APB-A1, a novel and well-differentiated anti-CD40 ligand (CD40L) antibody-like drug candidate, ready for phase I testing around the beginning of 2022. This […]
Collaboration - August 11, 2021
Lundbeck enters new research collaboration
Lundbeck will work together with the US-based Rgenta Therapeutics to discover small molecules targeting RNA regulation and splicing of disease-causing genes. “With this strategic R&D collaboration with Rgenta, we continue to supplement our research activities across the value chain. By using Rgenta’s platform capabilities in discovering RNA-targeting small molecules, we aim to pursue novel targets […]
Clinical Trials - April 21, 2021
Lundbeck continues brexpiprazole trial
Lundbeck and Otsuka announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer’s-type dementia. The decision to continue the trial is based on the results of an independent interim analysis, supporting to progress the trial to the planned full enrollment of 330 patients, announces the company in […]
In a new job - March 22, 2021
He is the new Head of Research at Lundbeck
Tarek Samad will join Lundbeck on 1 May 2021 as Senior Vice President, Head of Research. Samad will play a key role in Lundbeck’s ambition to have a premier neuroscience pipeline and to continue the transformation towards a focus on helping people living with niche and rare brain diseases, the company states. “I am pleased […]
Collaboration - January 15, 2021
Lundbeck and Rigshospitalet announce brain disease partnership
Lundbeck enters a partnership with the Department of Neurosurgery at Rigshospitalet, which will provide new insights into how molecules enter the brain. The partnership gives researchers an opportunity to study fluids surrounding the brain to learn which compounds enter the brain and how they are distributed. The findings will be published as basic research, but […]
